Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Nov 2016
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RESPONSE
- 24 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 24 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 17 Oct 2016 Status changed from recruiting to active, no longer recruiting.